CAROLYN HARRIS-MUCHELL: Open Payments
NPI 1619155280 · OAKLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 12 payments from 8 companies in 2025. Trend: 2023 $387 · 2024 $713 · 2025 $1,045
Food & beverage: $1,018Education: $27
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $294 |
| Alkermes, Inc. | 2 | $203 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $143 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Neurocrine BioSciences, Inc. | 1 | $110 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
Products named: INVEGA SUSTENNA, CAPLYTA, UZEDY, ARISTADA, INGREZZA, LYBALVI, COBENFY, Qelbree.
Industry payments across CA — which companies pay providers there.
